The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.

The changes of liver stiffness and its associated factors for chronic hepatitis B patients with entecavir therapy.

Liver stiffness measurement (LSM) using transient elastography has been proposed to assess liver fibrosis well in various liver diseases. This study was to determine the changes of LSM and its associated factors for chronic hepatitis B (CHB) patients undergoing Entecavir therapy. Consecutive CHB pat...

Full description

Bibliographic Details
Main Authors:	Yuan-Hung Kuo, Sheng-Nan Lu, Chien-Hung Chen, Kuo-Chin Chang, Chao-Hung Hung, Wei-Chen Tai, Ming-Chao Tsai, Po-Lin Tseng, Tsung-Hui Hu, Jing-Houng Wang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2014-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3969320?pdf=render

Similar Items

Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
by: Te-Ling Ma, et al.
Published: (2019-01-01)

The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
by: Yu-Chi Lee, et al.
Published: (2019-01-01)

Long-term risk of primary liver cancers in entecavir versus tenofovir treatment for chronic hepatitis B
by: Te-Sheng Chang, et al.
Published: (2021-01-01)

Liver stiffness measurement in cirrhotic patient — Implications of disease activity and treatment efficacy
by: Huang-Wei Xu, et al.
Published: (2012-12-01)

APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level.
by: Yi-Hao Yen, et al.
Published: (2018-01-01)

Liver stiffness measurement at complete virological response in hepatoma prediction for HBV‐related cirrhosis patient with potent antiviral agent
by: Jing‐Houng Wang, et al.
Published: (2019-11-01)

On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma
by: Hung-Wei Wang, et al.
Published: (2020-05-01)

Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
by: Guei-Ying Chen, et al.
Published: (2015-11-01)

Ultrasound-Based Liver Stiffness Surveillance in Patients Treated for Chronic Hepatitis B or C
by: Sheng-Hung Chen, et al.
Published: (2018-04-01)

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Ming-Chao Tsai, et al.
Published: (2021-09-01)

Reversal of Hypolipidemia in Chronic Hepatitis C Patients After Successful Antiviral Therapy
by: Yuan-Hung Kuo, et al.
Published: (2011-06-01)

Comparisons of noninvasive indices based on daily practice parameters for predicting liver cirrhosis in chronic hepatitis B and hepatitis C patients in hospital and community populations
by: Po-Lin Tseng, et al.
Published: (2013-07-01)

Effects of entecavir on inflammatory reaction, liver function and liver fibrosis in chronic hepatitis b patients
by: Qing-Qiang Wang, et al.
Published: (2018-07-01)

Impact of PNPLA3 and IFNL3 polymorphisms on hepatic steatosis in Asian patients with chronic hepatitis C.
by: Chao-Min Huang, et al.
Published: (2017-01-01)

Factors Predicting HBsAg Seroclearance and Alanine Transaminase Elevation in HBeAg-Negative Hepatitis B Virus-Infected Patients with Persistently Normal Liver Function.
by: Tai-Long Chien, et al.
Published: (2016-01-01)

Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C
by: Chao-Hung Hung, et al.
Published: (2016-04-01)

Clinical Implications of Alpha-fetoprotein in Chronic Hepatitis C
by: Wei-Chen Tai, et al.
Published: (2009-03-01)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
by: Ming-Te Kuo, et al.
Published: (2014-01-01)

Sustained virological response and metabolic risk factors are associated with mortality in patients with chronic hepatitis C.
by: Yi-Hao Yen, et al.
Published: (2019-01-01)

Changing serum levels of quantitative hepatitis B surface antigen and hepatitis B virus DNA in hepatitis B virus surface antigen carriers: A follow-up study of an elderly cohort
by: Yuan-Hung Kuo, et al.
Published: (2015-02-01)

HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients
by: Cheng-Yuan Peng, et al.
Published: (2015-04-01)

Significance of Vitamin D Receptor Gene Polymorphisms for Risk of Hepatocellular Carcinoma in Chronic Hepatitis C
by: Chao-Hung Hung, et al.
Published: (2014-08-01)

Experience of entecavir therapy in chronic hepatitis B
by: E. V. Esaulenko, et al.
Published: (2014-09-01)

Entecavir for the treatment of chronic hepatitis B infection
by: J Shepherd, et al.
Published: (2009-10-01)

Comparison of entecavir and adefovir for the treatment of chronic hepatitis B
by: Si-Hai Zhao, et al.

Baseline hepatitis B surface antigen quantitation can predict virologic response in entecavir-treated chronic hepatitis B patients
by: Chia-Chi Wang, et al.
Published: (2014-11-01)

Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs
by: Ming-Chao Tsai, et al.
Published: (2017-07-01)

Clinical utility of hepatitis C virus core antigen assay in the monitoring of direct-acting antivirals for chronic hepatitis C.
by: Sheng Feng Lin, et al.
Published: (2020-01-01)

Associated Factors for Metabolic Syndrome in the Older Adults with Chronic Virus Hepatitis in the Community.
by: Yuan-Hung Kuo, et al.
Published: (2016-01-01)

Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study
by: Yi-Hao Yen, et al.
Published: (2018-09-01)

Safety and efficacy of entecavir for the treatment of chronic hepatitis B
by: Melissa Osborn
Published: (2011-02-01)

Efficacy of entecavir treatment for patients with chronic hepatitis B
by: XIA Shulin
Published: (2015-04-01)

Adherence to entecavir for chronic hepatitis B and correlation with effectiveness
by: Vanessa Romero Díaz-Maroto, et al.
Published: (2015-11-01)

The efficacy and safety of entecavir in patients with chronic hepatitis B- associated liver failure: a meta-analysis
by: Xiaoguo Zhang, et al.
Published: (2015-03-01)

Hepatitis C core antigen highly correlated to HCV RNA
by: Christine Chang, et al.
Published: (2018-12-01)

Does Nucleos(t)ide Analogues Treatment Affect Renal Function in Chronic Hepatitis B Patients Who Have Already Decreased eGFR? A Longitudinal Study.
by: Ming-Chao Tsai, et al.
Published: (2016-01-01)

Elevated body mass index is a risk factor associated with possible liver cirrhosis across different etiologies of chronic liver disease
by: Yi-Hao Yen, et al.
Published: (2018-04-01)

Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B
by: Cheng-Hao Tseng, et al.
Published: (2018-10-01)

Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B
by: Sang Hoon Ahn, et al.
Published: (2013-12-01)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
by: Norio Itokawa, et al.
Published: (2021-01-01)